top of page

The Enemy of My Enemy: Can Bacteriophages Replace Antibiotics?

24m
6 min read

A quiet pandemic we built ourselves


In 1928, Alexander Fleming’s discovery of penicillin launched medicine into the antibiotic era. However, the most recent Global Burden of Disease analysis estimates that in 2021, 4.71 million deaths were associated with bacterial antimicrobial resistance (AMR), including 1.14 million deaths directly attributable to resistance, and this has become a burden comparable to HIV/AIDS or malaria. The World Health Organization’s 2024 Bacterial Priority Pathogens List identifies 24 resistant pathogens of urgent public-health concern, dominated by Gram-negative bacteria such as carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii. 


The pipeline for new antibiotics is thin, and resistance is not a problem that will solve itself. This is why bacteriophages: viruses that infect and kill bacteria, have moved from the past medical history back into the mainstream of antimicrobial research. The question is no longer whether phages can kill bacteria. It is whether they can be turned into reliable, regulated, clinically deployable medicines in place of, or alongside antibiotics.


A short history of a long relationship


Bacteriophages were discovered over a century ago. The microbiologist named Félix d’Hérelle used phage preparations to treat bacterial dysentery in children in 1919, decades before penicillin reached the market. Phage therapy programmes were established in Tbilisi (Georgia) and Wrocław (Poland), and both traditions persist today. In the West, however, the arrival of broad-spectrum antibiotics in the 1940s pushed phages aside. Antibiotics were easier to manufacture, easier to patent, and easier to prescribe without knowing the exact identity of the pathogen.


The revival of interest is not nostalgia. It is driven by necessity. Phages offer the target host specificity that antibiotics cannot. A phage typically infects only a narrow range of bacterial strains, leaving the rest of the microbiome intact. In an era when we increasingly understand that broad-spectrum antibiotic damage to the gut microbiota contributes to infection, metabolic disease, and immune dysregulation, that precision is not a luxury but  it is a design feature.


How phages work — and why that matters


Phages are viruses with a head (capsid) that protects their genetic material and a tail that recognises specific receptors on a bacterial cell surface. Most therapeutic candidates are Lytic phages: upon infection, they hijack the bacterium’s machinery, replicate, and burst the cell open, releasing new phage particles that go on to infect neighbouring bacteria. Temperate phages, by contrast, can integrate their genome into the bacterial chromosome and lie dormant; they are generally poor therapeutic choices unless engineered to be obligately lytic.


This lifestyle difference produces several clinically relevant properties:

Self-amplification

A phage replicates only where its host is present. This means a small initial dose can grow at the site of infection.

Biofilm penetration

Phages and phage-derived enzymes can degrade the extracellular matrix of bacterial biofilms, which antibiotics struggle to penetrate.

Microbiota sparing

Because phages are narrow-spectrum, they can suppress a disease-associated pathobiont without wiping out commensal bacteria.

Evolutionary trade-offs

In some cases, bacterial mutations that confer phage resistance also reduce virulence or restore antibiotic sensitivity — an effect that can be exploited therapeutically through “phage steering”.


However, these properties also create challenges. Narrow host range means a phage that works against one patient’s Pseudomonas strain may not work against another’s. Bacteria also carry multiple anti-phage defence systems : restriction-modification enzymes, CRISPR-Cas, and many more that can render phage treatment ineffective. And because phages are foreign proteins and nucleic acids, they can stimulate the immune system, particularly during repeated intravenous administration. 


Phages as precision microbiome editors


One of the most intellectually exciting developments is the use of phages not against acute infections, but against noncommunicable diseases (NCDs) driven by disease-contributing commensal bacteria.


The Elinav group’s Science Perspective describes proof-of-concept work in which phage combinations targeted antibiotic-resistant Klebsiella pneumoniae strains associated with inflammatory bowel disease (IBD) in mice, reducing inflammation and disease severity. Similar approaches have targeted K. pneumoniae clades enriched in primary sclerosing cholangitis and alcohol-producing K. pneumoniae in steatohepatitis. In cancer, phages engineered to bind Fusobacterium nucleatum in colorectal tumours have been used to deliver chemotherapy nanoparticles directly to the tumour microenvironment, improving drug efficacy while suppressing the pathobiont.


This is a fundamentally different therapeutic logic from antibiotics. Instead of killing broadly and accepting collateral damage, phage therapy asks: which bacterial strain is contributing to this disease, and can we remove it precisely? The same logic could eventually apply to metabolic disease, autoimmune conditions, and even neurodegeneration, where specific microbial signatures are increasingly implicated.


What stands between the Lab and the Clinic?


Narrow host range and the need for personalised cocktails. A phage that lyses one strain may be useless against another strain of the same species. This is why many groups are developing Phage cocktails: mixtures of phages that bind different receptors, to broaden coverage and reduce the emergence of resistance. But cocktails are harder to manufacture, characterise, and regulate than a single chemical entity.


Phage resistance and anti-phage immunity. Bacteria evolve resistance readily. The solution is not a single phage, but combination therapy and, increasingly, engineered phages. CRISPR-Cas-armed phages can be designed to target antibiotic-resistance genes or essential bacterial genes, reducing the emergence of phage-tolerant mutants. 


Delivery and pharmacokinetics. Orally administered phages face gastric acid, bile salts, and variable transit times. Encapsulation, timed-release formulations, and gastric acid suppression can improve delivery to the gut. For systemic infections, intravenous administration is increasingly used, but repeated dosing can elicit neutralising antibodies.


Manufacturing and regulation. Phages are live biological agents. Regulatory frameworks designed for small molecules and conventional biologics do not map neatly onto personalised phage cocktails.Phage biobanks: curated, sequenced, and structurally characterised collections, are one proposed solution to the availability problem.

The evidence gap. The most honest statement is that phage therapy is not yet proven to be superior to antibiotics in controlled trials. The 2025 meta-analysis found that efficacy improvement compared with control was not statistically significant. This does not mean phages do not work; it means the field needs larger, better-designed trials with standardised endpoints, phage characterisation, and long-term safety monitoring.


Antibiotics vs phages: a fair comparison

Feature 

Antibiotics 

Bacteriophages 

Spectrum 

Often broad 

Narrow, strain-specific 

Microbiome impact

Can cause collateral damage 

Minimal off-target dysbiosis 

Replication at infection site 

No 

Yes (self-amplifying) 

Biofilm penetration 

Variable 

Often effective 

Resistance mechanisms 

Well characterised; plasmid-borne resistance common 

Multiple bacterial defence systems; can be countered by cocktails and engineering 

Manufacturing 

Standardised chemical or fermentation process 

Biological production; requires host strain and purification 

Regulatory path 

Established 

No approved human-use product in EU/US; compassionate use and trials 

Personalisation 

Limited 

High — can be tailored to patient’s pathogen 


The future of phages as precision antimicrobials, but not a simple swap


The phrase “replacement for antibiotics” is useful but scientifically imprecise. The more realistic future is phages as a complementary precision antimicrobial platform and it is used where antibiotics fail, where resistance is present, or where microbiome preservation is critical.

Several trajectories are converging:


  • Engineered phages with expanded host ranges, CRISPR-armed killing, or anti-CRISPR payloads to overcome bacterial defences.


  • Phage-derived enzymes such as endolysins, which degrade peptidoglycan and can be formulated as non-living therapeutics without the immunogenicity of whole phages.


  • Companion diagnostics: metagenomic profiling of a patient’s pathobiont followed by rapid in vitro phage susceptibility testing to build a personalised cocktail.


  • Phage biobanks and AI-guided phage matching, which could reduce the time from diagnosis to treatment.


The regulatory landscape is slowly adapting. The EMA’s 2025 phage quality guidelines, the UK’s compassionate-use pathways, and the TATFAR cross-border dialogue all point toward a future in which phages are regulated as a distinct therapeutic class rather than squeezed into frameworks designed for chemical drugs.


Bacteriophages are not a silver bullet, and they are not yet a drop-in replacement for antibiotics. But they represent one of the most biologically elegant solutions to the AMR crisis: use the enemy of bacteria to kill bacteria precisely. The evidence to date , from compassionate-use cohorts, first-in-human trials, and preclinical NCD models, is encouraging enough to justify serious investment in rigorous clinical trials, tailored regulation, and manufacturing infrastructure. The question is no longer whether phages belong in the antimicrobial arsenal. It is how quickly we can build the evidence and systems to deploy them responsibly.



References

  1. Strathdee SA, Hatfull GF, Mutalik VK, Schooley RT. Phage therapy: From biological mechanisms to future directions. Cell. 2023;186(1):17–31. doi:10.1016/j.cell.2022.11.017.

  2. Kviatcovsky D, Valdés-Mas R, Federici S, Elinav E. Phage therapy in noncommunicable diseases. Science. 2023;382(6668):266–269. doi:10.1126/science.adh2718.

  3. GBD 2021 Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. Lancet. 2024;404(10459):1199–1226.

  4. World Health Organization. WHO bacterial priority pathogens list, 2024. Geneva: WHO; 2024.

  5. United Nations General Assembly. Political declaration of the high-level meeting on antimicrobial resistance. 26 September 2024.

  6. Clinical application of customized and non-customized bacteriophage therapy in patients with refractory/resistant bacterial infections: a systematic review and meta-analysis. Int J Antimicrob Agents. 2025. doi:10.1016/j.ijantimicag.2025.…

  7. Considerations and perspectives on phage therapy from the Transatlantic Task Force on Antimicrobial Resistance. Nat Commun. 2025;16:10883. doi:10.1038/s41467-025-64608-3.

  8. Overview of regulatory requirements for phage therapy among TATFAR member countries. Nat Commun. 2025;16:10883, Table 1.

  9. Phage treatment of multidrug-resistant bacterial infections in humans, animals, and plants: current status and future prospects. Clin Microbiol Infect. 2025.


This article was prepared by Yap Chi Keat (Yonsei University).


 
 
 

Comments


Stay Up-To-Date with New Posts

Search By Tags

© the Malaysian Bioscience Scholars est. 2017

bottom of page